Theravance Biopharma (TBPH) Current Taxes (2014 - 2026)

Theravance Biopharma (TBPH) has 4 years of Current Taxes data on file, last reported at $5.3 million in Q1 2026.

• Current Taxes for Q1 2026 came in at $5.3 million, down 9.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 9.67% YoY), and the FY2025 annual result was $5.3 million, down 9.67% from the prior year.
• Current Taxes held at $5.3 million in Q1 2026 per TBPH's latest filing, from $5.3 million in the prior quarter.
• Over five years, Current Taxes peaked at $26.7 million in Q2 2025 and troughed at $4.1 million in Q3 2025.
• A 3-year average of $8.8 million and a median of $5.6 million in 2024 frame the typical range for Current Taxes.
• On a YoY basis, Current Taxes climbed as much as 9.67% in 2025 and fell as far as 9.67% in 2025.
• A 3-year view of Current Taxes shows it stood at $5.9 million in 2024, then declined by 9.67% to $5.3 million in 2025, then changed by 0.0% to $5.3 million in 2026.
• Business Quant data shows TBPH's Current Taxes at $5.3 million in Q1 2026, $5.3 million in Q4 2025, and $4.1 million in Q3 2025.